Ralph A H Stewart1, Dominika Szalewska2, Lilin She3, Kerry L Lee4, Mark H Drazner5, Barbara Lubiszewska6, Dragana Kosevic7, Permyos Ruengsakulrach8, José C Nicolau9, Benoit Coutu10, Shiv K Choudhary11, Daniel B Mark12, John G F Cleland13, Ileana L Piña14, Eric J Velazquez12, Andrzej Rynkiewicz15, Harvey White16. 1. Green Lane Cardiovascular Service, Auckland City Hospital, and University of Auckland, Auckland, New Zealand. Electronic address: rstewart@adhb.govt.nz. 2. Medical University of Gdansk, Department of Rehabilitation, Gdansk, Poland. 3. Duke Clinical Research Institute, Clinical Trial Biostatistics, Durham, North Carolina. 4. Duke Clinical Research Institute, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina. 5. University of Texas Southwestern Medical Center, Dallas, Texas. 6. National Institute of Cardiology, Warsaw, Poland. 7. Dedinje Cardiovascular Institute, Belgrade, Serbia. 8. Bangkok Heart Hospital, Bangkok Hospital Group, Bangkok, Thailand. 9. Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil. 10. Hotel-Dieu du CHUM, Montreal, Canada. 11. All India Institute of Medical Sciences, New Delhi, India. 12. Duke Clinical Research Institute, Department of Medicine-Cardiology, Duke University School of Medicine, Durham, North Carolina. 13. Castle Hill Hospital/Hull Royal Infirmary, Kingston-upon-Hull, United Kingdom. 14. Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York. 15. University of Waria and Mazury, Department of Cardiology and Cardiosurgery, Olsztyn, Poland. 16. Green Lane Cardiovascular Service, Auckland City Hospital, and University of Auckland, Auckland, New Zealand.
Abstract
OBJECTIVES: The objective of this study was to assess the prognostic significance of exercise capacity in patients with ischemic left ventricular (LV) dysfunction eligible for coronary artery bypass graft surgery (CABG). BACKGROUND: Poor exercise capacity is associated with mortality, but it is not known how this influences the benefits and risks of CABG compared with medical therapy. METHODS: In an exploratory analysis, physical activity was assessed by questionnaire and 6-min walk test in 1,212 patients before randomization to CABG (n = 610) or medical management (n = 602) in the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Mortality (n = 462) was compared by treatment allocation during 56 months (interquartile range: 48 to 68 months) of follow-up for subjects able (n = 682) and unable (n = 530) to walk 300 m in 6 min and with less (Physical Ability Score [PAS] >55, n = 749) and more (PAS ≤55, n = 433) limitation by dyspnea or fatigue. RESULTS: Compared with medical therapy, mortality was lower for patients randomized to CABG who walked ≥300 m (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.59 to 0.99; p = 0.038) and those with a PAS >55 (HR: 0.79; 95% CI: 0.62 to 1.01; p = 0.061). Patients unable to walk 300 m or with a PAS ≤55 had higher mortality during the first 60 days with CABG (HR: 3.24; 95% CI: 1.64 to 6.83; p = 0.002) and no significant benefit from CABG during total follow-up (HR: 0.95; 95% CI: 0.75 to 1.19; p = 0.626; interaction p = 0.167). CONCLUSIONS: These observations suggest that patients with ischemic left ventricular dysfunction and poor exercise capacity have increased early risk and similar 5-year mortality with CABG compared with medical therapy, whereas those with better exercise capacity have improved survival with CABG. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595).
OBJECTIVES: The objective of this study was to assess the prognostic significance of exercise capacity in patients with ischemic left ventricular (LV) dysfunction eligible for coronary artery bypass graft surgery (CABG). BACKGROUND: Poor exercise capacity is associated with mortality, but it is not known how this influences the benefits and risks of CABG compared with medical therapy. METHODS: In an exploratory analysis, physical activity was assessed by questionnaire and 6-min walk test in 1,212 patients before randomization to CABG (n = 610) or medical management (n = 602) in the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Mortality (n = 462) was compared by treatment allocation during 56 months (interquartile range: 48 to 68 months) of follow-up for subjects able (n = 682) and unable (n = 530) to walk 300 m in 6 min and with less (Physical Ability Score [PAS] >55, n = 749) and more (PAS ≤55, n = 433) limitation by dyspnea or fatigue. RESULTS: Compared with medical therapy, mortality was lower for patients randomized to CABG who walked ≥300 m (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.59 to 0.99; p = 0.038) and those with a PAS >55 (HR: 0.79; 95% CI: 0.62 to 1.01; p = 0.061). Patients unable to walk 300 m or with a PAS ≤55 had higher mortality during the first 60 days with CABG (HR: 3.24; 95% CI: 1.64 to 6.83; p = 0.002) and no significant benefit from CABG during total follow-up (HR: 0.95; 95% CI: 0.75 to 1.19; p = 0.626; interaction p = 0.167). CONCLUSIONS: These observations suggest that patients with ischemic left ventricular dysfunction and poor exercise capacity have increased early risk and similar 5-year mortality with CABG compared with medical therapy, whereas those with better exercise capacity have improved survival with CABG. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595).
Authors: Stephan D Fihn; Julius M Gardin; Jonathan Abrams; Kathleen Berra; James C Blankenship; Apostolos P Dallas; Pamela S Douglas; Joanne M Foody; Thomas C Gerber; Alan L Hinderliter; Spencer B King; Paul D Kligfield; Harlan M Krumholz; Raymond Y K Kwong; Michael J Lim; Jane A Linderbaum; Michael J Mack; Mark A Munger; Richard L Prager; Joseph F Sabik; Leslee J Shaw; Joanna D Sikkema; Craig R Smith; Sidney C Smith; John A Spertus; Sankey V Williams Journal: Circulation Date: 2012-11-19 Impact factor: 29.690
Authors: Maria Clemencia Zuluaga; Pilar Guallar-Castillón; Esther López-García; José R Banegas; Manuel Conde-Herrera; Maite Olcoz-Chiva; Carlos Rodríguez-Pascual; Fernando Rodriguez-Artalejo Journal: Eur J Heart Fail Date: 2010-09-22 Impact factor: 15.534
Authors: Eric J Velazquez; Kerry L Lee; Marek A Deja; Anil Jain; George Sopko; Andrey Marchenko; Imtiaz S Ali; Gerald Pohost; Sinisa Gradinac; William T Abraham; Michael Yii; Dorairaj Prabhakaran; Hanna Szwed; Paolo Ferrazzi; Mark C Petrie; Christopher M O'Connor; Pradit Panchavinnin; Lilin She; Robert O Bonow; Gena Roush Rankin; Robert H Jones; Jean-Lucien Rouleau Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Anne B Newman; Eleanor M Simonsick; Barbara L Naydeck; Robert M Boudreau; Stephen B Kritchevsky; Michael C Nevitt; Marco Pahor; Suzanne Satterfield; Jennifer S Brach; Stephanie A Studenski; Tamara B Harris Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Lee Ingle; Alan S Rigby; Sean Carroll; Ron Butterly; Rod F King; Carlton B Cooke; John G J F Cleland; Andrew L Clark Journal: Eur Heart J Date: 2007-02-21 Impact factor: 29.983
Authors: V Bittner; D H Weiner; S Yusuf; W J Rogers; K M McIntyre; S I Bangdiwala; M W Kronenberg; J B Kostis; R M Kohn; M Guillotte Journal: JAMA Date: 1993-10-13 Impact factor: 56.272
Authors: David M Shahian; Sean M O'Brien; Giovanni Filardo; Victor A Ferraris; Constance K Haan; Jeffrey B Rich; Sharon-Lise T Normand; Elizabeth R DeLong; Cynthia M Shewan; Rachel S Dokholyan; Eric D Peterson; Fred H Edwards; Richard P Anderson Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: Andrew P Ambrosy; Susanna R Stevens; Hussein R Al-Khalidi; Jean L Rouleau; Nadia Bouabdallaoui; Peter E Carson; Christopher Adlbrecht; John G F Cleland; Rafal Dabrowski; Krzysztof S Golba; Ileana L Pina; Carla A Sueta; Ambuj Roy; George Sopko; Robert O Bonow; Eric J Velazquez Journal: Eur J Heart Fail Date: 2019-01-30 Impact factor: 15.534
Authors: Ralph A H Stewart; Dominika Szalewska; Amanda Stebbins; Hussein R Al-Khalidi; John G H Cleland; Andrzej Rynkiewicz; Mark H Drazner; Harvey D White; Daniel B Mark; Ambuj Roy; Dragana Kosevic; Miroslaw Rajda; Marek Jasinski; Chua Yeow Leng; Wiwun Tungsubutra; Patrice Desvigne-Nickens; Eric J Velazquez; Mark C Petrie Journal: Open Heart Date: 2018-02-20
Authors: Kenji Matsumoto; Yi Xiao; Shunichi Homma; John L P Thompson; Richard Buchsbaum; Kazato Ito; Stefan D Anker; Min Qian; Marco R Di Tullio Journal: ESC Heart Fail Date: 2020-12-30
Authors: Daniella Meeker; Jordan Goldberg; Katherine K Kim; Desi Peneva; Hugo De Oliveira Campos; Ross Maclean; Van Selby; Jason N Doctor Journal: J Med Internet Res Date: 2019-08-06 Impact factor: 5.428